Clinical trials: Endothelium, Vascular
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
HIV
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular…
- Trial name
- NCT01270802
- Testing
- Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Coronary Heart Disease
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents.
- Trial name
- NCT00655538
- Testing
- dalcetrapib
- Where
- 23 sites in Austria, France and 5 more
- Volunteers
- 476 people
- Sponsor
- Hoffmann-La Roche
Cardiovascular Disease, Cardiomyopathy
Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
The purpose of this study is to see if taking a cholesterol lowering drug Lipitor (Atorvastatin Calcium)will increase the number of endothelial progenitor cells (EPC's) circulating in the blood of heart failure patients taking…
- Conditions
- Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease
- Trial name
- NCT00701220
- Testing
- Atorvastatin Calcium
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Philip Binkley
Aging, Inflammation
Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
This study focuses on whether high cardiorespiratory fitness in older adults has a protective effect on the vascular response to acute inflammation in comparison to low-fit older and young adults.
- Trial name
- NCT03889158
- Testing
- Typhoid Vaccine, Ascorbic Acid
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Endothelial Dysfunction
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunction following 14 days of treatment by…
- Trial name
- NCT00532844
- Testing
- Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- BioMarin Pharmaceutical
Hypertension, Type 2 Diabetes Mellitus
Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
The purpose of this study is to compare the vascular effects of two commonly used blood pressure medications, carvedilol and metoprolol in hypertensive patients with type 2 diabetes.
- Trial name
- NCT00123604
- Testing
- Carvedilol, Metoprolol
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- St. Paul Heart Clinic
Obesity, Prehypertension
Vascular Dysfunction in Human Obesity Hypertension
The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure.
- Conditions
- Obesity, Prehypertension, Hypertension
- Trial name
- VANISH (NCT01983462)
- Testing
- Clonidine, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gary L. Pierce
Renal Insufficiency, Chronic
Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)
Risk of cardiovascular diseases (CVD) is significantly elevated in patients with chronic kidney disease (CKD); however, this increased risk is only partially explained by traditional cardiovascular risk factors.
- Trial name
- NCT01663103
- Testing
- Rilonacept
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
Free Fatty Acids and Vascular Function in Subjects With Diabetes
This study will test the hypothesis that reduction in release of free fatty acids from adipocytes will restore insulin-mediated endothelium-dependent vasodilation and skeletal muscle glucose metabolism in subject with type 2…
- Trial name
- NCT00153179
- Testing
- acipimox
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Although multiple studies have suggested that treatment with ranibizumab is safe and efficacious and superior to focal/grid laser alone for patients with center-involved diabetic macular edema (DME), there may be barriers in…
- Trial name
- Protocol T (NCT01627249)
- Testing
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Where
- 90 sites in United States
- Volunteers
- 660 people
- Sponsor
- Jaeb Center for Health Research
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hypertriglyceridemia
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.
- Trial name
- OMEGA (NCT00504309)
- Testing
- 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Penn State University
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Cancer, Non Small Cell Lung Cancer
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
The purpose of this study is to determine whether using two drugs together called vandetanib and selumetinib is effective in the treatment of cancer.
- Trial name
- NCT01586624
- Testing
- Vandetanib, Selumetinib
- Where
- 4 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Cancer Research UK
HIV, Inflammation
PET/CT Imaging Companion Study To ACTG A5314
HIV-infected individuals on antiretroviral therapy (ART) are at increased risk for cardiovascular disease (CVD), likely due to chronically increased inflammation.
- Conditions
- HIV, Inflammation, Atherosclerosis
- Trial name
- PET/CTMTX (NCT02312219)
- Testing
- Folic Acid, Low Dose Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Chronic Kidney Disease, Cardiovascular Disease
Phosphate Lowering in CKD Trial
The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries in adults with moderate to…
- Trial name
- NCT02209636
- Testing
- Lanthanum carbonate, Ascorbic Acid, Nitroglycerin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi